NORTHWEST BIOTHERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| | NORTHWEST BIOTHERAPEUTICS, INC.(Registrant) | |
|---|---|---|
| Date: March 31, 2025 | By: | /s/ Linda F. Powers |
| | | Linda F. Powers, |
| | | President and Chief Executive Officer Principal Executive OfficerPrincipal Financial and Accounting Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| | | |||
| Signature | Title | Date | ||
|---|---|---|---|---|
| /s/ Linda F. Powers | | President and Chief Executive Officer | | March 31, 2025 |
| Linda F. Powers | | Principal Executive Officer | | |
| | | Principal Financial and Accounting Officer | | |
| | | | | |
| /s/ Alton L. Boynton | | Director | | March 31, 2025 |
| Alton L. Boynton | | | | |
| | | | | |
| /s/ Navid Malik | | Director | | March 31, 2025 |
| Dr. Navid Malik | | | | |
| | | | | |
| /s/ Pat Sarma | | Director | | March 31, 2025 |
| Pat Sarma | | | | |
| | | | | |
| /s/ J. Cofer Black | | Director | | March 31, 2025 |
| J. Cofer Black | | | | |
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS
| Reports of Independent Registered Public Accounting Firm (PCAOB ID 00677) | F-2 |
|---|---|
| | |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-4 |
| | |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 | F-5 |
| | |
| Consolidated Statements of Changes in Stockholders’ Deficit for the years ended December 31, 2024 and 2023 | F-6 |
| | |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-7 |
| | |
| Notes to the Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.